Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4960 |
Name | bone marrow cancer |
Definition | A hematopoietic cancer that derives_from the blood-forming stem cells of the bone marrow. |
Source | DiseaseOntology.org |
Alt Ids | DOID:2356 DOID:2761 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CBL mutant | Quizartinib | bone marrow cancer | sensitive | detail... |
JAK2 V617F | SGI-1776 | bone marrow cancer | decreased response | detail... |
JAK2 V617F | AZD1208 | bone marrow cancer | decreased response | detail... |
JAK2 V617F | Ruxolitinib + SGI-1776 | bone marrow cancer | sensitive | detail... |
JAK2 V617F | AZD1208 + Ruxolitinib | bone marrow cancer | sensitive | detail... |
JAK2 V617F | CHZ868 | bone marrow cancer | sensitive | detail... |
CSF3R mutant | N/A | bone marrow cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00620633 | Phase I | ATA520 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Completed | USA | 0 |
NCT00679536 | Phase Ib/II | anti-thymocyte globulin + Busulfan + Fludarabine | Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | Unknown status | USA | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT00892190 | Phase I | Dasatinib | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT00908167 | Phase I | Clofarabine + Cytarabine + Sorafenib | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT01584531 | Phase II | Rigosertib Sodium | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01593670 | Phase II | Decitabine Aldesleukin Vorinostat | Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | Completed | USA | 0 |
NCT01606579 | Phase Ib/II | Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | Completed | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01634217 | Phase I | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | Completed | USA | 0 | |
NCT01640301 | Phase Ib/II | Aldesleukin WT1 sensitized T cells | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | Terminated | USA | 0 |
NCT01687400 | Phase II | Decitabine | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | Completed | USA | 0 |
NCT01720225 | Phase II | Decitabine Azacitidine | Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | Completed | USA | 0 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01812252 | Phase II | Cytarabine + Idarubicin Azacitidine + Decitabine | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01823198 | Phase Ib/II | Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim | Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies | Completed | USA | 0 |
NCT01834248 | Phase I | Decitabine + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01841333 | Phase II | Glasdegib | PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01842646 | Phase II | Glasdegib | Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT01869114 | Phase II | Azacitidine + Sirolimus | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | Active, not recruiting | USA | 0 |
NCT01880437 | Phase II | Cytarabine + Vismodegib | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome | Terminated | USA | DEU | CAN | 0 |
NCT01885689 | Phase II | Clofarabine + Melphalan | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission | Active, not recruiting | USA | 0 |
NCT01893320 | Phase Ib/II | Decitabine + Vosaroxin | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01895842 | Phase I | Ruxolitinib | Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT01926587 | Phase Ib/II | Azacitidine + Regorafenib | Oral Rigosertib in Combination With Azacitidine | Completed | USA | FRA | 0 |
NCT01928537 | Phase III | Rigosertib Sodium | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | Completed | USA | SWE | ITA | FRA | ESP | DNK | DEU | AUS | 0 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01993641 | Phase II | Pracinostat Azacitidine Decitabine | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | Completed | USA | 0 |
NCT02010645 | Phase II | Decitabine + Eltrombopag | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02076191 | Phase Ib/II | Decitabine + Ruxolitinib | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | Completed | USA | 0 |
NCT02078609 | Phase I | LGH447 | A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | Completed | USA | NLD | ITA | FRA | DEU | AUS | 1 |
NCT02083250 | Phase I | anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine | Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia | Completed | USA | 0 |
NCT02103478 | Phase Ib/II | Decitabine and Cedazuridine | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS | Completed | USA | CAN | 0 |
NCT02121418 | Phase I | Cytarabine + Decitabine | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | Completed | USA | 0 |
NCT02129101 | Phase I | Azacitidine Sonidegib | Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies | Completed | USA | 0 |
NCT02131597 | Phase II | Guadecitabine | SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT02141477 | Phase II | Decitabine + Omacetaxine mepesuccinate | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02212561 | Phase Ib/II | Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02296242 | Phase Ib/II | Ulixertinib | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | Completed | USA | 0 |
NCT02308761 | Phase I | TEN-010 | A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02312102 | Phase I | Bortezomib + Lenalidomide | Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02319369 | Phase I | Milademetan | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies | Terminated | USA | 0 |
NCT02333162 | Phase I | Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT02381548 | Phase I | Adavosertib + Belinostat | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02392572 | Phase Ib/II | ONC201 | ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS) | Recruiting | USA | 0 |
NCT02400281 | Phase Ib/II | Azacitidine Crenolanib Cytarabine + Idarubicin | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | Completed | USA | 0 |
NCT02418000 | Phase Ib/II | E6201 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation | Terminated | USA | 0 |
NCT02464657 | Phase Ib/II | Dexamethasone Cytarabine + Idarubicin + Nivolumab | Nivolumab in Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02469415 | Phase II | Decitabine Azacitidine Pacritinib | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | Terminated | USA | 0 |
NCT02472145 | Phase III | Decitabine Decitabine + Talacotuzumab | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | Completed | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 3 |
NCT02485535 | Phase I | Selinexor | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | Completed | USA | 0 |
NCT02527174 | Phase I | Cytarabine + Idarubicin + Volasertib | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) | Withdrawn | CAN | 0 |
NCT02530476 | Phase Ib/II | Selinexor + Sorafenib | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02577406 | Phase III | Azacitidine Cytarabine Enasidenib | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) | Completed | USA | TUR | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 4 |
NCT02599649 | Phase II | Nivolumab Azacitidine Lirilumab | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Terminated | USA | 0 |
NCT02610777 | Phase II | Azacitidine MLN4924 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Completed | USA | NLD | ITA | ISR | IRL | FRA | ESP | DEU | CZE | CAN | BGR | BEL | 0 |
NCT02721875 | Phase I | Azacitidine Volasertib | Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Terminated | 1 | |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02728050 | Phase Ib/II | Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone | Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03065400 | Phase II | Pembrolizumab | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | Completed | USA | 0 |